Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003 (First Quarter of Fiscal 2004)
Business Overview: The Company operates four reportable segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The quarter included the full impact of the Syncor International Corporation acquisition completed in January 2003.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2004 (Sep 30, 2003) | Q1 2003 (Sep 30, 2002) |
|---|---|---|
| Operating Revenue | $13,288.3 | $11,416.6 |
| Operating Gross Margin | $1,083.2 | $1,006.9 |
| Operating Earnings | $522.4 | $467.5 |
| Net Earnings | $328.6 | $288.3 |
| Diluted EPS | $0.74 | $0.64 |
| Cash and Equivalents (Ending) | $992.0 | $945.6 |
| Net Cash from Operating Activities | $294.1 | $(14.1) |
| Total Debt (Current + Long-term) | $2,724.0 | Filing text does not provide a clear comparative total for 2002 |
Note: Bulk deliveries to customer warehouses ($2,100.4M) are reported as revenue but generate zero gross margin.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 16% year-over-year, driven by higher sales volume, new customer agreements, and the inclusion of Syncor. The Pharmaceutical Technologies and Services segment saw the highest growth at 57%.
- Profitability: Operating earnings rose 12% to $522.4 million. Net earnings increased 14% to $328.6 million.
- Cash Flow: Net cash provided by operating activities improved significantly to $294.1 million from a use of $14.1 million in the prior year, primarily due to a $866.9 million increase in accounts payable and a reduction in bad debt provisions.
- Share Repurchases: The Company executed a $1.0 billion share repurchase program, buying back approximately 17.0 million shares at an average price of $58.65. This resulted in a net decrease in cash and equivalents of $732.0 million for the quarter.
- Working Capital: Working capital decreased to $5.3 billion from $5.9 billion, largely due to the cash outflow from share repurchases and increased inventory levels ($630.4 million increase).
Guidance, Outlook, Risks, and Unusual Items
Special Items and Restructuring
Total special items for the quarter were $13.2 million (net of tax: $8.7 million reduction in earnings), compared to $18.7 million in the prior year. These included:
- Merger-Related Costs: $8.6 million, primarily related to the integration of Syncor.
- Restructuring: $5.8 million for manufacturing facility closures and restructurings, expected to result in the termination of approximately 850 employees over fiscal 2004 and 2005.
- Future Estimates: Management estimates an additional $85 million in future merger and restructuring costs (approx. $55 million net of tax).
Legal Proceedings and Contingencies
- Latex Litigation: 149 lawsuits pending regarding natural rubber latex sensitization. Potential liability is estimated between $0 and $20 million net of insurance, deemed immaterial.
- Syncor Litigation: Multiple shareholder class actions and derivative suits alleging improper payments and fiduciary breaches related to the Syncor acquisition. The Company believes these are without merit and expects insurance coverage for a portion of any liability.
- SEC Inquiry: The Company received an informal inquiry from the SEC regarding the accounting treatment of $22 million recovered from vitamin manufacturers.
- DuPont Litigation: A lawsuit filed by DuPont alleging patent infringement and false advertising regarding surgical drapes and gowns.
Subsequent Events
On November 1, 2003, the Company commenced a cash offer to acquire The Intercare Group for approximately $530 million, including the assumption of $124 million in debt.
Investor Verification Checklist
- Share Repurchase Impact: Verify the effect of the $1 billion treasury stock purchase on liquidity and future capital allocation flexibility.
- Syncor Integration Costs: Monitor the realization of the estimated $85 million in future restructuring and integration costs.
- Legal Exposure: Track developments in the Syncor shareholder litigation and the SEC informal inquiry regarding vitamin settlement accounting.
- Margin Pressure: Assess the impact of reduced vendor margin programs and competitive pricing on the Pharmaceutical Distribution segment's gross margins.
- Inventory Levels: Review the $630 million increase in inventories to ensure it aligns with demand and does not signal future write-downs.